SC 13G: Avalo Therapeutics, Inc.

AI Summary

SC 13G filing by Avalo Therapeutics, Inc..

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.001 — INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securiti

Filing Documents

• d722112dsc13g.htm (SC 13G) — 60KB
• d722112dex991.htm (EX-99.1) — 4KB
• 0001193125-24-234002.txt ( ) — 65KB

From the Filing

SC 13G 1 d722112dsc13g.htm SC 13G SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AVALO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 05338F306 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ). Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications: Evan K. Hall, Esq. Haynes and Boone, LLP 2801 N. Harwood Street, Suite 2300 Dallas, Texas 75201 (214) 651-5000 SCHEDULE 13G CUSIP No. 05338F306 1 Names of Reporting Persons Ikarian Capital, LLC 2 Check the appropriate box if a member of a Group (see instructions) (a)(b) 3 Sec Use Only 4 Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power 0 6 Shared Voting Power 970,359 (1) 7 Sole Dispositive Power 0 8 Shared Dispositive Power 970,359 (1) 9 Aggregate Amount Beneficially Owned by Each Reporting Person 970,359 (1) 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) 11 Percent of class represented by amount in row (9) 10.02% (1)(2) 12 Type of Reporting Person (See Instructions) IA (1) Represents shares held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership, and certain separately managed accounts. See Item 2 for more information. (2) Based upon 9,682,374 shares of Common Stock, $0.001 par value, outstanding as of September 30, 2024, as disclosed by the Issuer to the Reporting Persons on October 4, 2024. SCHEDULE 13G CUSIP No. 05338F306 1 Names of Reporting Persons Neil Shahrestani 2 Check the appropriate box if a member of a Group (see instructions) (a)(b) 3 Sec Use Only 4 Citizenship or Place of Organization United States Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power 0 6 Shared Voting Power 970,359 (1) 7 Sole Dispositive Power 0 8 Shared Dispositive Power 970,359 (1) 9 Aggregate Amount Beneficially Owned by Each Reporting Person 970,359 (1) 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) 11 Percent of class represented by amount in row (9) 10.02% (1)(2) 12 Type of Reporting Person (See Instructions) IN;HC (1) Represents shares held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership, and certain separately managed accounts. See Item 2 for more information. (2) Based upon 9,682,374 shares of Common Stock, $0.001 par value, outstanding as of September 30, 2024, as disclosed by the Issuer to the Reporting Persons on October 4, 2024. Item1. (a) Name of Issuer: Avalo Therapeutics, Inc., a Delaware corporation (the Issuer ). (b) Address of Issuers Principal Executive Offices: 540 Gaither Road, Suite 400, Rockville, Maryland 20850 Item2. (a) Name of Person Filing: This statement is filed jointly by and on behalf of each of Ikarian Capital, LLC, a Delaware limited liability company ( Ikarian Capital ), and Neil Shahrestani (together referred herein as the Reporting Persons ). Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the Fund ), and certain separately managed accounts managed by Ikarian Capital (collectively, the Managed Accounts ) are the record owners of the securities covered by this statement. Ikarian Capital is an investment adviser registered under the Investment Advisers Act of 1940, as amended, and serves as investment manager to the Fund and as sub-adviser to the Managed Accounts, and may be deemed to have beneficial ownership of the securities covered by this statement through the investment discretion it has over the Fund and the Managed Accounts. Ikarian Capital is ultimately controlled, indirectly, by Mr. Shahrestani. Accordingly, Mr. Shahrestani may be deemed to indirectly beneficially own securities beneficially owned by Ikarian Capital. The Fund disclaims beneficial ownership of the shares hel

View Full Filing

View this SC 13G filing on SEC EDGAR